352 related articles for article (PubMed ID: 21434697)
1. Five-year examination of utilization and drug cost outcomes associated with benefit design changes including reference pricing for proton pump inhibitors in a state employee health plan.
Johnson JT; Neill KK; Davis DA
J Manag Care Pharm; 2011 Apr; 17(3):200-12. PubMed ID: 21434697
[TBL] [Abstract][Full Text] [Related]
2. Effects on the cost and utilization of proton pump inhibitors from adding over-the counter omeprazole to drug benefit coverage in a state employee health plan.
Harris BN; West DS; Johnson J; Hong SH; Stowe CD
J Manag Care Pharm; 2004; 10(5):449-55. PubMed ID: 15369428
[TBL] [Abstract][Full Text] [Related]
3. A 30-month evaluation of the effects on the cost and utilization of proton pump inhibitors from adding omeprazole OTC to drug benefit coverage in a state employee health plan.
West DS; Johnson JT; Hong SH
J Manag Care Pharm; 2006; 12(1):25-32. PubMed ID: 16420105
[TBL] [Abstract][Full Text] [Related]
4. Effect of a therapeutic maximum allowable cost (MAC) program on the cost and utilization of proton pump inhibitors in an employer-sponsored drug plan in Canada.
Mabasa VH; Ma J
J Manag Care Pharm; 2006 Jun; 12(5):371-6. PubMed ID: 16792443
[TBL] [Abstract][Full Text] [Related]
5. Cost and Utilization Outcomes After Exclusion of Dipeptidyl Peptidase-4 Inhibitors and Other Diabetes Drug Category Changes in a Self-Funded, State Employee Managed Care Plan.
King J; McAdam-Marx C; McCaleb R; Davis D; Bemberg GB; Johnson JT
J Manag Care Spec Pharm; 2019 Jun; 25(6):646-651. PubMed ID: 31134855
[TBL] [Abstract][Full Text] [Related]
6. Proton-pump inhibitor utilization associated with the change to nonpreferred formulary status for esomeprazole in the TRICARE formulary.
Linton A; Bacon T; Peterson M
J Manag Care Pharm; 2009; 15(1):42-54. PubMed ID: 19125549
[TBL] [Abstract][Full Text] [Related]
7. Effect on drug utilization and expenditures of a cost-share change from copayment to coinsurance.
Klepser DG; Huether JR; Handke LJ; Williams CE
J Manag Care Pharm; 2007; 13(9):765-77. PubMed ID: 18062728
[TBL] [Abstract][Full Text] [Related]
8. Comparison of mail-order with community pharmacy in plan sponsor cost and member cost in two large pharmacy benefit plans.
Johnsrud M; Lawson KA; Shepherd MD
J Manag Care Pharm; 2007 Mar; 13(2):122-34. PubMed ID: 17330973
[TBL] [Abstract][Full Text] [Related]
9. Utilization, cost trends, and member cost-share for self-injectable multiple sclerosis drugs--pharmacy and medical benefit spending from 2004 through 2007.
Kunze AM; Gunderson BW; Gleason PP; Heaton AH; Johnson SV
J Manag Care Pharm; 2007; 13(9):799-806. PubMed ID: 18062731
[TBL] [Abstract][Full Text] [Related]
10. Pharmacy benefit spending on oral chemotherapy drugs.
Curtiss FR
J Manag Care Pharm; 2006 Sep; 12(7):570-7. PubMed ID: 16981802
[TBL] [Abstract][Full Text] [Related]
11. Cost and utilization of behavioral health medications associated with rescission of an exemption for prior authorization for severe and persistent mental illness in the Vermont Medicaid Program.
Simeone JC; Marcoux RM; Quilliam BJ
J Manag Care Pharm; 2010 Jun; 16(5):317-28. PubMed ID: 20518584
[TBL] [Abstract][Full Text] [Related]
12. Community pharmacy and mail order cost and utilization for 90-day maintenance medication prescriptions.
Khandelwal N; Duncan I; Rubinstein E; Ahmed T; Pegus C
J Manag Care Pharm; 2012 Apr; 18(3):247-55. PubMed ID: 22468733
[TBL] [Abstract][Full Text] [Related]
13. Pharmacist and physician satisfaction and rates of switching to preferred medications associated with an instant prior authorization program for proton pump inhibitors in the North Carolina Medicaid program.
Jacobson Vann JC; Christofferson S; Humble CG; Wegner SE; Feaganes JR; Trygstad TK
J Manag Care Pharm; 2010 May; 16(4):250-63. PubMed ID: 20433216
[TBL] [Abstract][Full Text] [Related]
14. Effects of a step-therapy program for angiotensin receptor blockers on antihypertensive medication utilization patterns and cost of drug therapy.
Yokoyama K; Yang W; Preblick R; Frech-Tamas F
J Manag Care Pharm; 2007 Apr; 13(3):235-44. PubMed ID: 17407390
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of product switching after a state Medicaid program began covering loratadine OTC 1 year after market availability.
Trygstad TK; Hansen RA; Wegner SE
J Manag Care Pharm; 2006 Mar; 12(2):108-20. PubMed ID: 16515369
[TBL] [Abstract][Full Text] [Related]
16. Utilization and drug cost outcomes of a step-therapy edit for generic antidepressants in an HMO in an integrated health system.
Dunn JD; Cannon E; Mitchell MP; Curtiss FR
J Manag Care Pharm; 2006 May; 12(4):294-302. PubMed ID: 16792435
[TBL] [Abstract][Full Text] [Related]
17. Relationship of the use and costs of physician office visits and prescription drugs to travel distance and increases in member cost share.
Cecil WT; Barnes J; Shea T; Coulter SL
J Manag Care Pharm; 2006 Oct; 12(8):665-76. PubMed ID: 17269845
[TBL] [Abstract][Full Text] [Related]
18. Prescription drug costs and the generic dispensing ratio.
Liberman JN; Roebuck MC
J Manag Care Pharm; 2010 Sep; 16(7):502-6. PubMed ID: 20726679
[TBL] [Abstract][Full Text] [Related]
19. A therapeutic substitution policy for proton pump inhibitors: clinical and economic consequences.
Schneeweiss S; Maclure M; Dormuth CR; Glynn RJ; Canning C; Avorn J
Clin Pharmacol Ther; 2006 Apr; 79(4):379-88. PubMed ID: 16580906
[TBL] [Abstract][Full Text] [Related]
20. Analysis of nonformulary use of PPIs and excess drug cost in a Veterans Affairs population.
Ajumobi AB; Vuong R; Ahaneku H
J Manag Care Pharm; 2012; 18(1):63-7. PubMed ID: 22235956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
